Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts-Reference-Cited by-同舟云学术

Antibody response after third dose of COVID-19 mRNA vaccination in allogeneic hematopoietic stem cell transplant recipients is comparable to that in healthy counterparts

Published:2023-08-10 Issue:4 Volume:118 Page:462-471
ISSN:0925-5710
Container-title:International Journal of Hematology
language:en
Short-container-title:Int J Hematol

Author:

Takagi Erina,Terakura Seitaro^ORCID,Fujigaki Hidetsugu,Okamoto Akinao,Miyao Kotaro,Sawa Masashi,Morishita Takanobu,Goto Tatsunori,Ozawa Yukiyasu,Nishida Tetsuya,Fukushima Nobuaki,Ozeki Kazutaka,Hanajiri Ryo,Saito Kuniaki,Murata Makoto,Tomita Akihiro,Kiyoi Hitoshi

Funder

Japan Society for the Promotion of Science (JSPS) KAKENHI

Publisher

Springer Science and Business Media LLC

Subject

Hematology

Link

https://link.springer.com/content/pdf/10.1007/s12185-023-03648-1.pdf

Reference21 articles.

1. Ministry of Health LaW: Visualizing the data: information on COVID-19 infections. https://covid19.mhlw.go.jp/en/ (2023). Accessed 12 May 2023

2. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577.

3. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA COVID-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23. https://doi.org/10.1056/NEJMoa2101765.

4. Tseng HF, Ackerson BK, Luo Y, Sy LS, Talarico CA, Tian Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 Omicron and Delta variants. Nat Med. 2022;28(5):1063–71. https://doi.org/10.1038/s41591-022-01753-y.

5. Okamoto A, Fujigaki H, Iriyama C, Goto N, Yamamoto H, Mihara K, et al. CD19-positive lymphocyte count is critical for acquisition of anti-SARS-CoV-2 IgG after vaccination in B-cell lymphoma. Blood Adv. 2022;6(11):3230–3. https://doi.org/10.1182/bloodadvances.2021006302.